Analyst Ratings For Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Today, B. Riley initiated coverage on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a Buy with a price target of $4.50.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) is Buy with a consensus target price of $4.1250 per share, a potential 232.66% upside.
Some recent analyst ratings include
- 7/31/2018-B. Riley initiated coverage with a Buy rating.
- 4/23/2018-MED Reiterated Rating of Positive.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
- 1/10/2017-FBR & Co Reiterated Rating of Buy.
Recent Insider Trading Activity For Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has insider ownership of 7.20% and institutional ownership of 3.97%.
- On 3/16/2018 Mark Germain, Director, sold 45,873 with an average share price of $1.48 per share and the total transaction amounting to $67,892.04.
- On 3/14/2018 Mark Germain, Director, sold 23,818 with an average share price of $1.50 per share and the total transaction amounting to $35,727.00.
- On 2/22/2016 Zami Aberman, CEO, bought 5,000 with an average share price of $1.33 per share and the total transaction amounting to $6,650.00.
- On 2/18/2016 Yaky Yanay, CFO, bought 5,000 with an average share price of $1.20 per share and the total transaction amounting to $6,000.00.
- On 2/16/2016 Yaky Yanay, CFO, bought 15,000 with an average share price of $0.95 per share and the total transaction amounting to $14,250.00.
- On 2/15/2016 Doron Shorrer, Director, bought 12,346 with an average share price of $0.81 per share and the total transaction amounting to $10,000.26.
- On 2/12/2016 Yaky Yanay, CFO, bought 5,000 with an average share price of $0.83 per share and the total transaction amounting to $4,150.00.
About Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Recent Trading Activity for Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Shares of Pluristem Therapeutics Inc. closed the previous trading session at 1,23 +0,0031 0,25 % with 1.23 shares trading hands.